Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Distribution and antibiotic resistance profile of key gram-negative bacteria that cause community-onset urinary tract infections in the Russian Federation: RESOURCE multicentre surveillance 2017 study.

Rafalskiy V, Pushkar D, Yakovlev S, Epstein O, Putilovskiy M, Tarasov S, Glazunov A, Korenev S, Moiseeva E, Gorelysheva N.

J Glob Antimicrob Resist. 2019 Sep 13. pii: S2213-7165(19)30241-3. doi: 10.1016/j.jgar.2019.09.008. [Epub ahead of print]

PMID:
31525541
2.

[Resistance of urinary tract pathogens and the choice of antimicrobial therapy: deceptive simplicity].

Rafalskiy VV, Dovgan EV.

Urologiia. 2017 Jul;(3):104-110. Review. Russian.

PMID:
28845948
3.

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group.

N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.

4.

Sharing Data from Cardiovascular Clinical Trials--A Proposal.

Academic Research Organization Consortium for Continuing Evaluation of Scientific Studies--Cardiovascular (ACCESS CV), Patel MR, Armstrong PW, Bhatt DL, Braunwald E, Camm AJ, Fox KA, Harrington RA, Hiatt WR, James SK, Kirtane AJ, Leon MB, Lincoff AM, Mahaffey KW, Mauri L, Mehran R, Mehta SR, Montalescot G, Nicholls SJ, Perkovic V, Peterson ED, Pocock SJ, Roe MT, Sabatine MS, Sekeres M, Solomon SD, Steg G, Stone GW, Van de Werf F, Wallentin L, White HD, Gibson M.

N Engl J Med. 2016 Aug 4;375(5):407-9. doi: 10.1056/NEJMp1605260. No abstract available.

5.

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators.

N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225.

6.

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.

Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Mathieu C, Woo V, Wysham C, Capuano G, Desai M, Shaw W, Vercruysse F, Meininger G, Neal B; CANVAS trial collaborative group.

Diabetes Obes Metab. 2016 Jan;18(1):82-91. doi: 10.1111/dom.12589. Epub 2015 Dec 8.

PMID:
26450639
7.

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.

Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA; ELIXA Investigators.

Am Heart J. 2015 May;169(5):631-638.e7. doi: 10.1016/j.ahj.2015.02.002. Epub 2015 Feb 12.

PMID:
25965710
8.

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees and Investigators.

Eur J Heart Fail. 2013 Sep;15(9):1062-73. doi: 10.1093/eurjhf/hft052. Epub 2013 Apr 5.

9.

Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease.

Evstatiev R, Alexeeva O, Bokemeyer B, Chopey I, Felder M, Gudehus M, Iqbal T, Khalif I, Marteau P, Stein J, Gasche C; FERGI Study Group.

Clin Gastroenterol Hepatol. 2013 Mar;11(3):269-77. doi: 10.1016/j.cgh.2012.10.013. Epub 2012 Oct 16.

PMID:
23078888

Supplemental Content

Loading ...
Support Center